Ignite Creation Date:
2024-05-05 @ 4:56 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00358410
Status:
COMPLETED
Last Update Posted:
2017-02-08
First Post:
2006-07-27
Brief Title:
An Exploratory Study Examining The Effects Of Taking GW679769 Once-Daily For 4 Days In Patients With Functional Dyspepsia
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
An Exploratory Study to Investigate the Effects of the NK1 Antagonist GW679769 60 mg Once Daily for 4 Days on Gastric Accommodation Gastric Emptying and Gastric Distension-induced Perception and Discomfort in Adult Male and Female Patients With Functional Dyspepsia in a Single Center Placebo-controlled Double-blind Randomised Two-period Crossover Study
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study was designed is to examine the idea that GW679769 has an effect on three of the pathophysiological disturbances reported in patients with Functional Dyspepsia FD impaired stomach accommodation to a meal delayed stomach emptying and visceral hypersensitivity to distension
Detailed Description:
An exploratory study to investigate the effects of the NK1 antagonist GW679769 120 mg once daily for 4 days on gastric accommodation gastric emptying and gastric distension-induced perception and discomfort in adult male and female patients with functional dyspepsia in a single-centre placebo-controlled double-blind randomised two-period crossover study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None